

1 **Increased mortality associated with uncontrolled diabetes mellitus in patients with**
2 **Pulmonary Cryptococcosis — a single U.S. cohort study**

3 Solana Archuleta¹, Amal A. Gharamti², Stefan Sillau³, Paula Castellanos⁴, Sindhu Chadawalada⁵,
4 William Mundo¹, Mehdi Bandali¹, Jose Oñate⁶, Ernesto Martínez⁶, Daniel Chastain⁷, Kristen
5 DeSanto⁸, Leland Shapiro^{4,9-10}, Ilan S. Schwartz¹¹, Carlos Franco-Paredes^{4,12}, Andrés F. Henao-
6 Martínez⁴

7 ¹School of Medicine, ³Department of Neurology, and ⁴Department of Medicine, Division of Infectious
8 Diseases, University of Colorado Denver, Aurora, CO, USA

9 ²Department of Internal Medicine, American University of Beirut, Beirut, Lebanon

10 ⁴Universidad de Manizales, Manizales, Colombia.

11 ⁵NRI General Hospital, India

12 ⁶Universidad del Valle, Cali, Colombia

13 ⁷Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy,
14 Albany, Georgia, USA.

15 ⁸Health Sciences Library, University of Colorado Denver, Aurora, Colorado, USA

16 ⁹Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO, USA

17 ¹⁰ The Emily Foundation for Medical Research, One Beacon Street, 15th Floor, Boston MA 02108,
18 United States

19 ¹¹Division of Infectious Diseases, Department of Medicine, Faculty of Medicine & Dentistry, University
20 of Alberta, Edmonton, AB, Canada

21 ¹²Hospital Infantil de México, Federico Gómez, México City, México

22 *Corresponding author: Andrés F. Henao-Martínez, MD, University of Colorado Denver 12700
23 E. 19th Avenue, Mail Stop B168. Aurora, CO 80045; Email:
24 andres.henaomartinez@cuanschutz.edu Tel.: +1 (720)-848-0820; fax: +1 (720)-848-0191.

25 ORCID number: 0000-0001-7363-8652

26 **Short title:** Increased cryptococcosis mortality associated with diabetes mellitus

27 **Keywords:** Cryptococcosis, *Cryptococcus*, Diabetes Mellitus, glycemic levels, mortality, risk

28 factors.

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49 **Abstract:**

50 **Background:** Diabetes mellitus is an established risk factor for bacterial infections, but its role
51 in Cryptococcosis is unclear. The study aimed to determine whether uncontrolled diabetes
52 (HbA1c >7%) was an independent risk factor for mortality in cryptococcosis.

53 **Methods:** A retrospective case-control study partially matched by age and gender was performed
54 in patients tested for *Cryptococcus* infection at the University of Colorado Hospital from 2000-
55 2019. A multivariable logistic regression model was used to identify mortality predictors. Cox
56 proportional hazard model was used for survival analysis.

57 **Results:** We identified 96 cases of Cryptococcosis and 125 controls. Among cases, cryptococcal
58 meningitis (49.0%) and pneumonia (36.5%) constituted most infections. Cases with pulmonary
59 cryptococcosis had a higher mortality at 10 weeks (50% vs 7%, $p=0.006$) and one year (66.7% vs
60 13.8%, $p=0.005$). Unadjusted Cox proportional hazard model found an increased rate of death
61 for uncontrolled diabetes at 10-weeks (hazard ratio 8.4, CI: 1.4-50.8, $p=0.02$), and 1-year (hazard
62 ratio 7.0, CI: 1.7-28.4, $p=0.007$) among pulmonary cryptococcosis cases. Multivariable analysis
63 showed a significantly increased odds of 10-weeks (OR=4.3, CI: 1.1-16.5, $p=0.035$) and one-
64 year (OR=5.9, CI: 2.2-15.8, $p=0.014$) mortality for uncontrolled diabetes among pulmonary
65 cryptococcosis cases. After adjustment for gender, age, and case/control, for every 1% increase
66 in HbA1c levels, the odds of pulmonary cryptococcosis mortality at one-year increased by 11%
67 (OR = 1.6, CI 95%: 1.1-2.3, $p= 0.006$).

68 **Conclusion:** Uncontrolled diabetes is associated with worse outcomes in pulmonary
69 cryptococcosis, including a 4-fold and 6-fold increased odds of death at 10-weeks and 1-year,
70 respectively. Glucose control interventions should be explored to improve clinical outcomes in
71 patients with pulmonary cryptococcosis.

72 **Introduction:**

73 Diabetes mellitus (diabetes) is one of the most prevalent non-communicable diseases in
74 the United States. The American Diabetes Association estimates 34.2 million Americans (10.5%
75 of the population) are affected (1), and the prevalence increases with age. Among those aged 65
76 or older, diabetes is present in 26.8%. A common complication among patients with diabetes is
77 infections, which carries a higher risk of mortality compared to adults without diabetes (2).
78 Pneumonia and sepsis are the most common infections associated with mortality in diabetes. The
79 pathogenesis of hyperglycemia-induced immune dysfunction includes reduced neutrophil
80 chemotaxis, adhesion, and migration, and decreased intracellular production of hydrogen
81 peroxide (3, 4). Diabetes is also a known risk factor for invasive fungal infections, such as
82 mucormycosis (5). However, we lack reports of diabetes or increased glucose levels as
83 independent risk factors for opportunistic infections commonly affecting advanced
84 immunocompromised states, including *Cryptococcus*.

85 Cryptococcosis continues to be a source of morbidity and mortality —up to 20% —
86 among immunocompromised hosts (6). Cryptococcal meningitis has a significant global impact
87 with 181,100 deaths each year among HIV-infected individuals (7). Moreover, developing
88 countries have seen an increasing incidence of the disease among non-HIV
89 immunocompromised hosts as well (8, 9). Solid-organ transplantation, systemic lupus
90 erythematosus, malignancy, sarcoidosis, and cirrhosis are conditions of functional
91 immunosuppression known to increase the risk for *Cryptococcus* spp. infection (10-15). Diabetes
92 mellitus is often listed as an additional risk factor for Pulmonary cryptococcosis especially
93 among HIV-negative patients (16, 17).

94 Diabetes is a common comorbidity among adult patients in the U.S. with Cryptococcosis.
95 However, the role of diabetes in the prevalence and associated mortality of *Cryptococcus*
96 infections is not well defined. The study aimed to determine whether diabetes and HbA1c levels
97 were independent risk factors for mortality in *Cryptococcus* infection.

98 **Methods:**

99 Ethics statement:

100 The present investigation is in the Health Insurance Portability and Accountability Act
101 (HIPAA) compliance and was approved by the Colorado Multiple Institutional Review Board
102 (COMIRB) at the University of Colorado Denver. Analysis of clinical data has been performed
103 under an approved protocol (COMIRB Protocol 15-1340), and an exemption of informed
104 consent was granted.

105 Patients and data collection:

106 We collected data on all patients with culture from any site that grew *Cryptococcus* or
107 with detection of antigens from serum or cerebrospinal fluid [CSF] diagnosed at the University
108 of Colorado Hospital microbiology laboratory between January 2000 and October 2019.

109 Controls were randomly chosen among patients with negative serum and when done,
110 CSF cryptococcal antigen and culture. A manual chart review was performed to exclude clinical
111 diagnoses of Cryptococcosis in these patients. Controls were partially matched to cases by
112 specimen collection date, age, and biological sex. Controls were mainly hospitalized and also
113 ambulatory patients from the same community served by the University of Colorado Hospital.
114 Most control patients had suspicions of having Cryptococcosis based on their underlying
115 immunosuppressive state and clinical concerns for meningitis or abnormal pulmonary findings.

116 The cryptococcal antigen tests used were an enzyme immunoassay test (Meridian
117 Premier Cryptococcal assay) before 2013, and the lateral flow assay (CrAg® LFA, Immuno-
118 Mycologics Inc. [IMMY], Norman, OK) after 2013. Cryptococcal meningitis was diagnosed
119 based on a positive cryptococcal CSF antigen or positive CSF culture. The assay didn't
120 differentiate the species of *Cryptococcus*. Medical reports were manually accessed to collect
121 clinical and laboratory variables for all patients. The following data was retrospectively collected
122 through RedCap (electronic data capture tools hosted at the University of Colorado Denver):
123 demographics (gender, race, and age); symptoms (constitutional, headaches, altered mental
124 status, respiratory abnormalities, fever, and others), medical history (smoking, lung disease,
125 diabetes, hypertension, lupus, malignancy, sarcoidosis, cirrhosis, HIV infection, solid organ
126 transplant, use of calcineurin inhibitors or corticosteroids, and prednisone dose); transplant (type
127 and time since transplant); vital signs at collection times (systolic blood pressure, diastolic blood
128 pressure, pulse, and temperature); weight, and body mass index (BMI); diagnosis of cryptococcal
129 meningitis; laboratory results (complete blood cell count, comprehensive metabolic panel,
130 baseline renal function, and blood culture), and outcomes of cryptococcal infection: 10- weeks,
131 1-year, and overall mortality (per consensus criteria established by the Mycoses Study Group and
132 European Organization for Research and Treatment of Cancer (18)), cognitive deficits, muscle
133 weakness, speech difficulties, hearing impairment, stroke by MRI results; and use of
134 ventriculoperitoneal shunts (VPS). Uncontrolled diabetes was defined as the most recent HbA1c
135 level >7%. Electronic medical records (EPIC, Verona, WI) were automatically interrogated for
136 A1C levels and date of death from the cohort of patients through software supported by Health
137 Data Compass Data Warehouse project (healthdatacompass.org). The most recent HbA1c

138 available before admission was chosen for analysis. The vast majority of patients with a
139 diagnosis of diabetes had an HbA1c level available.

140 Statistical analysis:

141 Statistical analyses were performed using STATA software, version 12.1 (StataCorp,
142 College Station, Texas, USA). We had crude mortality as our primary outcome at 70 days, and
143 one year. The means and standard deviations for continuous variables were calculated. For
144 categorical variables, frequencies and percentages were calculated. We initially performed a
145 bivariate analysis for dichotomous outcomes variables using chi-squared, and the Fisher exact
146 test for dichotomous and nominal independent variables, respectively. For interval independent
147 variables, we used the t-test. The uncontrolled diabetes group was compared to patients with
148 controlled diabetes ($HbA1c \leq 7\%$) or no diabetes. For the multivariable analysis, we selected age,
149 sex, commonly known cryptococcosis risk factors (HIV, solid organ transplant, cirrhosis,
150 malignancy, and steroids), smoking, factors associated with increased mortality in
151 Cryptococcosis (altered mental status and positive blood cultures for Cryptococcus), and case vs
152 control status. We did not include co-linear variables. Selected variables were included in a
153 multivariable, forward, stepwise logistic regression model. A parallel conditional logistic
154 regression model was run for comparison. Kaplan–Meier survival curves were constructed to
155 show cumulative mortality over the study period for Cryptococcosis cases by uncontrolled
156 diabetes mellitus status. Cox regression was used to estimate the mortality rate ratio among
157 pulmonary cryptococcosis cases with and without uncontrolled diabetes. Due to heterogeneous
158 controls, we also run a propensity score matching analysis. Linearity between HbA1c and days
159 from diagnosis to death was checked using a scatter plot and R-squared/adjusted R-squared from
160 ANOVA.

161 Data access

162 The corresponding author had full access to data in the study and had final responsibility for the
163 decision to submit the manuscript for publication. The datasets generated and analyzed in the
164 current study are available from the corresponding author on reasonable request.

165 **Results:**

166 We included a total of 96 cases and 125 controls. At least 55 cases and 112 controls were
167 matched by specimen collection date, age, and gender.

168 Clinical characteristics of patients with Cryptococcosis

169 Most subjects were men (79%). The average age was 54.1 years, and most subjects were
170 Caucasian with an upper limit of normal BMI. Diabetes was present in about a quarter of the
171 cases, with no statistical difference with controls. Among cases, cryptococcal meningitis (49.0%)
172 and pneumonia (36.5%) constituted most infections; followed by skin (8.3%), and asymptomatic
173 antigenemia (6.3%). Other common risk factors among cases were HIV (38.9%), steroid use
174 (24.7%), malignancy (21.1%), solid organ transplantation (18.1%), and cirrhosis (5.2%). Overall
175 mortality was similar among cases and controls (38.5% vs. 39.2%, $p=0.921$).

176 Clinical characteristics of patients with Pulmonary Cryptococcosis:

177 Pulmonary cryptococcosis cases ($n=35$) were older and were more likely to be HIV
178 negative (table 1). They commonly presented with respiratory symptoms as opposed to
179 headaches and altered mental status. Controls shared similar demographics and risk factors.
180 Mean hemoglobin and platelet levels were within or close to normal limits and similar among the
181 two groups. Creatinine levels were similar among cases and controls. Although HbA1c levels
182 were higher among pulmonary cryptococcosis cases, they were not statistically significant. ICU
183 stay, overall mortality, and mortality at 10 weeks and one year were similar to controls.

184 Clinical factors associated with an increase of 10-weeks and 1-year mortality from

185 Cryptococcosis

186 We found 10-weeks and 1-year mortality of 19% and 22% among cryptococcosis cases. The 10-
187 weeks mortality was significantly higher in cases compared to controls (18.8% vs 9.6%,
188 $p=0.049$). At 10 weeks, diabetes mellitus (44.4% vs 21.8%, $p=0.048$) and uncontrolled diabetes
189 (31.3% vs 7.9%, $p=0.009$) were more commonly present in those who died. Conversely,
190 transplant recipients are less likely to die shortly after diagnosis (5.6% vs 21%, $p=0.001$). Altered
191 mental status, anemia, and lower mean platelet count associate with an increase in 10-weeks
192 mortality (table 2). At 1-year, transplant recipients maintained lower mortality compared to non-
193 transplant recipients (5.9% vs 29.9%, $p=0.04$). Patients with a history of malignancy were more
194 like to die at 1 year (40.9% vs 20.6%, $p=0.05$), as well as patients with a history of uncontrolled
195 diabetes (54.5% vs 19.8%, $p=0.01$), and patients with altered mental status (47.8% vs 17.8%,
196 $p=0.004$) or respiratory symptoms (34.8% vs 17%, $p=0.04$). At 1-year, non-survivors had lower
197 hemoglobin levels (10.8 ± 2.4 vs 12.1 ± 2.6 mg/dL, $p=0.03$), and higher HbA1c levels ($7.8 \pm 1.9\%$
198 vs $6.1 \pm 1.1\%$, $p=0.003$). Cryptococcosis patients who died at 10-weeks and 1-year had more
199 commonly a history of speech difficulties and ICU stay. Among cryptococcosis cases, the 10-
200 weeks and one-year mortality was higher among those with uncontrolled diabetes: 45.5% vs
201 13.6%, $p=0.009$, and 54.5% vs 19.8%, $p=0.01$ respectively.

202 Unadjusted Cox proportional hazard model found an increased rate of death for uncontrolled
203 diabetes at 10-weeks (hazard ratio 3.7, CI: 1.3-10.8, $p=0.01$), and 1-year (hazard ratio 3.4, CI:
204 1.3-8.8, $p=0.01$) (figure 1). After adjustment for gender, age, and case/control; for every 1%
205 increase in A1c levels, the odds of mortality increased by 40% (OR = 1.4, CI 95%: 1.0-1.9, $p=$

206 0.045). The Scatter plot showed some degree of linearity and the ANOVA R-squared/Adjusted
207 R-squared was 95% and 6% respectively.

208 The multivariable analysis adjusted by gender, age, case/control, common risk factors for
209 Cryptococcosis (solid organ transplantation, steroid use, HIV infection, and smoking history),
210 and factors associated with increased mortality (altered mental status and positive blood cultures
211 for *Cryptococcus*), revealed an independent risk of death with uncontrolled diabetes
212 (HbA1c>7%) at 10-weeks (OR=3.6, CI: 1.1-12.3, p=0.037) and 1-year (OR=6.6, CI: 2.0-21.4,
213 p=0.002) (Table 3).

214 The propensity score matching with the exposure confounders revealed an ATE of 0.3 (p=0.03),
215 and 0.4 (p=0.0001) at 10-weeks and 1-year respectively for uncontrolled diabetics. Expressing
216 these results on a percentage scale, the chance of dying at 10-weeks and one-year is higher by
217 30% and 40% percentage points for uncontrolled diabetics. A multivariable sensitivity analysis
218 of the cohort —excluding controls with diabetes but without substantial hyperglycemia (HbA1c
219 < 7%)— showed also an independent risk of death with uncontrolled diabetes (HbA1c>7%) at
220 10-weeks (OR=4.3, CI: 1.3-14.4, p=0.02) and 1-year (OR=6.8, CI: 2.1-22.9, p=0.002). The MV
221 analysis also showed a significant increase in 10-weeks (OR: 6.0, CI: 1.5-24.1, p=0.012) and 1-
222 year mortality (OR: 4.4, CI: 1.5-13.0), p=0.008) using a different HbA1c cutoff (HbA1c >8%) as
223 uncontrolled diabetes.

224 Clinical factors associated with an increase of 10-weeks and 1-year mortality from Pulmonary
225 Cryptococcosis and meningitis

226 For cryptococcal meningitis cases only, the mortality was higher for those with uncontrolled
227 diabetes at 10 weeks (50% vs 19.1%, p=0.289) and one-year (50% vs 26.2%, p=0.46), although

228 not statistically significant. Cases with pulmonary cryptococcosis had a higher mortality at 10
229 weeks (50% vs 7%, $p=0.006$) and one year (66.7% vs 13.8%, $p=0.005$)

230 Unadjusted Cox proportional hazard model found an increased rate of death for uncontrolled
231 diabetes at 10-weeks (hazard ratio 8.4, CI: 1.4-50.8, $p=0.02$), and 1-year (hazard ratio 7.0, CI:
232 1.7-28.4, $p=0.007$) among pulmonary cryptococcosis cases (figure 2).

233 Multivariable analysis showed a significantly increased odds of 10-weeks (OR=4.3, CI: 1.1-16.5,
234 $p=0.035$) and one-year (OR=5.9, CI: 2.2-15.8, $p=0.014$) mortality for uncontrolled diabetes
235 among pulmonary cryptococcosis cases only. Malignancy was also independently associated
236 with increased mortality.

237 Clinical features and outcomes of cryptococcosis cases with diabetes and uncontrolled diabetes

238 Diabetes was the only known risk factor in 6 cases (6.3%), with 4 of these cases
239 complicated by chronic kidney disease; diabetes coexisted with additional risk factors in 19 cases
240 (19.8%). Mean HbA1c values were 5.4%, 6.9%, and 8.5% among cases without diabetes, cases
241 with diabetes and additional risk factors, and cases with diabetes only as a risk factor,
242 respectively. Cases with diabetes as a risk factor were older and had higher BMIs. They also
243 were more likely to have a solid organ transplant as a risk factor, and less likely to be HIV-
244 positive or current smokers. HbA1c levels were higher than 7% in 31.4% of the cryptococcosis
245 cases. Labs showed a statistically significantly lower mean of hemoglobin levels ($p=0.007$) and
246 an increase in the mean of creatinine levels ($p=0.002$) among cryptococcal cases with diabetes.
247 Cases with diabetes also had a non-statistically higher rate of paucicellular CSF values. Only one
248 of the six cases with only diabetes as a risk factor had disseminated disease or cryptococcal
249 meningitis. Patients with diabetes showed no statistically significant higher rates of ICU stay,
250 death within 10-weeks, or death within one year, but they have an increased overall death rate

251 (any death recorded during the study period) (60% vs 31%, $p=0.01$, rate ratio 2.5, CI: 1.3-4.8,
252 $p=0.007$). Stroke as a complication was seen more often in patients with diabetes, but this
253 association was not statistically significant.

254 Uncontrolled diabetes patients had a lower rate of HIV infection (9% vs 45%, $p=0.02$),
255 were older (64 ± 8.8 vs 52 ± 14.6 , $p=0.008$), and had most likely a pulmonary cryptococcal
256 infection (54% vs 38.8%, $p=0.02$). Their BMI was also higher than controlled or non-diabetics,
257 although this was not statistically significant.

258 **Discussion:**

259 We found in this single retrospective case-control study of 35 patients with pulmonary
260 Cryptococcosis an association of uncontrolled diabetes ($HbA1c >7\%$) with an increase of 10-
261 weeks and 1-year mortality. These findings remained after adjusting for commonly known
262 Cryptococcosis risk factors and other factors associated with disease mortality. Although the
263 association remained for all Cryptococcosis cases, the effect seems to be driven mainly by the
264 pulmonary cases.

265 Survival curves demonstrated a decreased chance of survival among patients with
266 Cryptococcosis—and also pulmonary cryptococcosis—and uncontrolled diabetes compared to
267 Cryptococcosis patients without diabetes or with controlled diabetes. This difference was evident
268 early in the diagnosis. Death from Cryptococcosis among people with diabetes in our cohort
269 approached 20% at 10-weeks and 22% at 1-year, which was comparable with other cohorts.
270 Uncontrolled diabetes correlates with increased age, end-organ failure, the presence of
271 comorbidities, and a suboptimal immune response. Poor glycemic control associates with
272 increased rates of serious infections and infection-related hospitalizations (19). These factors
273 could play a role in the observed increased mortality in Cryptococcosis.

274 We also found diabetes to be common comorbidity among patients with *Cryptococcus*
275 infection, and it often accompanied other established risk factors, particularly transplant status
276 and malignancy. Diabetes as the only identifiable risk factor was relatively uncommon, although
277 it was frequently complicated by chronic kidney disease. A recent case series identified
278 cryptococcal meningitis as a complication of patients with nephrotic syndrome (20). The
279 presence of diabetes mellitus translated into an observed increased chance of overall death, but it
280 was not associated with an increase in 10-weeks or 1-year mortality.

281 Other U.S. cryptococcosis cohorts have reported a prevalence of diabetes of around 20%
282 (21), similar to ours of 25%. These numbers correlate with the number of people living with
283 diabetes based on age in the U.S. (1). An Argentinian study found a marked increase in mortality
284 in Cryptococcal meningitis patients with AIDS and diabetes compared to those with AIDS
285 without diabetes (85.7% vs 21.4%) (22). Matched cohort studies have identified a 20% increase
286 in the risk of any infection among patients with diabetes (23). This risk is modulated by
287 increasing HbA1c levels (19). Since compromised cell-mediated immunity is present in most
288 patients affected with Cryptococcosis, one possible mechanistic explanation is the altered
289 function of CD8⁺ T-cells and natural killer cells in patients with diabetes (24). Decreased
290 macrophage and cytokine function (such as interleukin-12) may play a role as well (25, 26).
291 Patients with diabetic nephropathy may also confer additional immune response impairments.
292 Reports have shown impairments in cell-mediated immunity in chronic kidney disease (27),
293 including decreased CD4 and CD8 cell lines (28) and T-cell proliferation (29). Solid organ
294 transplant recipients often receive steroids as part of their immunosuppressive regimens, which
295 in turn increases the risk to develop diabetes. The presence of diabetes in invasive infections
296 often increases the risk of multiorgan injury and death (30).

297 Some cohorts haven't found diabetes as a predictor of mortality with Cryptococcosis (6,
298 31), but those cohorts didn't list the HbA1c levels, which is more specific for diabetes-associated
299 complications. However, in a case series of 30 cases of Cryptococcosis in Diabetics in mainland
300 China, 57% of patients didn't list an additional underlying risk factor, and 40% had non-
301 disseminated pulmonary cryptococcosis (32). A case-control study in Taiwan found HIV-
302 negative patients with Cryptococcosis were more likely to have diabetes (OR: 1.5), and the
303 presence of diabetes was also associated with an increase in 1-year mortality from
304 Cryptococcosis (33). Finally, a case series in Japan found diabetes mellitus in 32% of patients
305 with pulmonary cryptococcosis (17).

306 We also found that non-survivors at 1-year had lower hemoglobin levels and higher
307 HbA1c levels. The relationship between HbA1c levels and mortality may not be completely
308 linear. There is evidence to suggest that HbA1C values are affected by changes in the erythrocyte
309 lifespan. Iron-deficiency anemia, which increases the lifespan of erythrocytes resulting in
310 increased glycation, is associated with falsely elevated HbA1C values. Other types of anemia,
311 like hemolytic anemia, decrease the lifespan of erythrocytes. This is associated with falsely
312 decreased HbA1C levels (34, 35). In this study, uncontrolled diabetes (HbA1C level >7%) was
313 found to be a significant predictor of mortality in patients with *Cryptococcus* infection. Since
314 non-survivors had a mean hemoglobin level of 10.4, anemia could be a possible confounder.

315 Pulmonary Cryptococcosis was independently associated with an increase in 10-weeks
316 and one-year mortality risk. Although cryptococcal meningitis had higher mortality rates at the
317 same timepoints, it did not reach statistical difference. Possible explanations are the low number
318 of cases studied or intrinsic factors of hosts with pulmonary cryptococcosis driving the mortality
319 differences. Malignancy can be more common among patients with pulmonary Cryptococcosis

320 as opposed to Cryptococcal meningitis. However, the association of mortality with uncontrolled
321 diabetes remained after adjusting for this variable.

322 Another finding was that transplant recipients had lower mortality at 1-year compared to
323 non-transplant patients. This is consistent with the literature, in which transplant status is
324 associated with lower mortality compared to non-transplant status (36, 37). Delay in diagnosis in
325 HIV-negative, non-transplant patients compared to transplant recipients associates with worse
326 outcomes.

327 There are a few limitations to this study. The retrospective selection of data limits the
328 reliability of the predictors and limits the number of variables analyzed. We could not control for
329 all variables associated with Cryptococcal mortality due to missing available data in our cohort.
330 Some selection bias may exist as different observers worked on data collection. Also, the number
331 of cases with uncontrolled diabetes was relatively low, contributing to a lack of power. We
332 employed measures to reduce biases by adjusting for confounders. Controls were identified by a
333 negative cryptococcal antigen, which may not be representative of the overall at-risk population
334 and biases towards the null underestimating of the possible effects. Finally, since data was
335 collected over two decades and some out-of-the-state deaths might haven't been recorded, death
336 rates could've been underestimated. However, our paper has been the best exercise you can do to
337 try to answer the role of uncontrolled diabetes mellitus in Cryptococcal mortality with limited
338 available data. A low prevalence of these patients hampers investigations designed to establish
339 the role of glucose levels in mortality in patients with Cryptococcosis. A definitive understanding
340 of glucose levels with mortality in these patients necessitates large prospective studies.
341 Collecting sufficient patients for this kind of definitive study is not feasible since it would
342 require excessively prolonged periods of subject accrual and multi-institution enrollment.

343 Therefore, single-institution retrospective studies can generate new hypotheses and unveil or
344 propose new associations.

345 Diabetes alone is an uncommon but possible risk factor by itself for acquiring
346 *Cryptococcus* infection. It commonly accompanies additional risk factors, and it can be
347 complicated by chronic kidney disease. Uncontrolled diabetes in Cryptococcosis—but especially
348 pulmonary infection— may worsen outcomes from infection, leading to increased mortality. It
349 remains to be determined whether glucose control interventions can improve clinical outcomes in
350 patients with cryptococcal infection, and we need follow-up studies for validation of the findings
351 in additional external cohorts.

352 **Funding:**

353 This research received no specific grant from any funding agency in the public,
354 commercial, or not-for-profit sectors.

355

356 **Declaration of Conflicting Interests**

357 The authors declare that there are no conflicts of interest.

358 **Authors contributions:**

359 Conceptualization and design: SA, SS, AHM; data acquisition: SA, PC, KS, AHM; data analysis
360 and interpretation: AHM, CFP, IS; original draft writing: SA, AHM; original draft review and
361 editing: AG, PC, SC, WM, MB, JO, EM, DC, KD, LS, IS, CFP; statistical analysis: SS, AHM;
362 supervision: CFP, AHM

363

364

365

366 **References:**

- 367 1. (CDC) CfDcAP. National Diabetes Statistics Report 2020 [Available from:
368 <https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf>.
- 369 2. Bertoni AG, Saydah S, Brancati FL. Diabetes and the Risk of Infection-Related Mortality
370 in the U.S. *Diabetes Care*. 2001;24(6):1044-9.
- 371 3. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review
372 of pathogenesis. *Indian journal of endocrinology and metabolism*. 2012;16(Suppl1):S27.
- 373 4. Alba-Loureiro TC, Hirabara SM, Mendonca JR, Curi R, Pithon-Curi TC. Diabetes causes
374 marked changes in function and metabolism of rat neutrophils. *J Endocrinol*. 2006;188(2):295-
375 303.
- 376 5. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of Mucormycosis.
377 *Clinical Infectious Diseases*. 2012;54(suppl_1):S16-S22.
- 378 6. Brizendine KD, Baddley JW, Pappas PG. Predictors of mortality and differences in
379 clinical features among patients with Cryptococcosis according to immune status. *PloS one*.
380 2013;8(3):e60431.
- 381 7. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global
382 burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. *Lancet Infect*
383 *Dis*. 2017;17(8):873-81.
- 384 8. George IA, Spec A, Powderly WG, Santos CAQ. Comparative Epidemiology and
385 Outcomes of Human Immunodeficiency virus (HIV), Non-HIV Non-transplant, and Solid Organ
386 Transplant Associated Cryptococcosis: A Population-Based Study. *Clinical Infectious Diseases*.
387 2018;66(4):608-11.

- 388 9. Kashef Hamadani BH, Franco-Paredes C, McCollister B, Shapiro L, Beckham JD,
389 Henao-Martinez AF. Cryptococcosis and cryptococcal meningitis: New predictors and clinical
390 outcomes at a United States academic medical centre. *Mycoses*. 2017.
- 391 10. Baddley JW, Perfect JR, Oster RA, Larsen RA, Pankey GA, Henderson H, et al.
392 Pulmonary cryptococcosis in patients without HIV infection: factors associated with
393 disseminated disease. *European journal of clinical microbiology & infectious diseases* : official
394 publication of the European Society of Clinical Microbiology. 2008;27(10):937-43.
- 395 11. Wang LR, Barber CE, Johnson AS, Barnabe C. Invasive fungal disease in systemic lupus
396 erythematosus: a systematic review of disease characteristics, risk factors, and prognosis.
397 *Seminars in arthritis and rheumatism*. 2014;44(3):325-30.
- 398 12. Cancelli I, Merlino G, Serafini A, Valente M, Gigli GL. Sarcoidosis as risk factor for
399 cryptococcal meningitis in an apparently immunocompetent patient. *Neurological sciences* :
400 official journal of the Italian Neurological Society and of the Italian Society of Clinical
401 Neurophysiology. 2008;29(1):33-5.
- 402 13. Lin YY, Shiau S, Fang CT. Risk factors for invasive *Cryptococcus neoformans* diseases:
403 a case-control study. *PloS one*. 2015;10(3):e0119090.
- 404 14. Henao-Martinez AF, Beckham JD. Cryptococcosis in solid organ transplant recipients.
405 *Current opinion in infectious diseases*. 2015;28(4):300-7.
- 406 15. Henao-Martinez AF, Gross L, McNair B, McCollister B, DeSanto K, Montoya JG, et al.
407 Risk Factors for Cryptococcal Meningitis: A Single United States Center Experience.
408 *Mycopathologia*. 2016;181(11-12):807-14.
- 409 16. Setianingrum F, Rautemaa-Richardson R, Denning DW. Pulmonary cryptococcosis: A
410 review of pathobiology and clinical aspects. *Med Mycol*. 2019;57(2):133-50.

- 411 17. Kohno S, Kakeya H, Izumikawa K, Miyazaki T, Yamamoto Y, Yanagihara K, et al.
412 Clinical features of pulmonary cryptococcosis in non-HIV patients in Japan. *J Infect Chemother.*
413 2015;21(1):23-30.
- 414 18. Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, et al.
415 Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases:
416 Mycoses Study Group and European Organization for Research and Treatment of Cancer
417 consensus criteria. *Clin Infect Dis.* 2008;47(5):674-83.
- 418 19. Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG. Glycemic Control
419 and Risk of Infections Among People With Type 1 or Type 2 Diabetes in a Large Primary Care
420 Cohort Study. *Diabetes Care.* 2018;41(10):2127-35.
- 421 20. Hu D, Zhang Q, Jiang W, Arastehfar A, Ilkit M, Fang W, et al. Cryptococcal Meningitis:
422 A Rare Complication in HIV-Negative Patients with Nephrotic Syndrome in A Chinese
423 Teaching Hospital. *Mycopathologia.* 2020:1-11.
- 424 21. George IA, Spec A, Powderly WG, Santos CAQ. Comparative Epidemiology and
425 Outcomes of Human Immunodeficiency virus (HIV), Non-HIV Non-transplant, and Solid Organ
426 Transplant Associated Cryptococcosis: A Population-Based Study. *Clinical infectious diseases :*
427 an official publication of the Infectious Diseases Society of America. 2018;66(4):608-11.
- 428 22. Messina FA, Negroni R, Maiolo EI, Arechavala A, Villafañe MF, Santiso G, et al.
429 Criptococosis meníngea en pacientes con diabetes y sida. *Enfermedades Infecciosas y*
430 *Microbiología Clínica.* 2014;32(10):643-6.
- 431 23. Abu-Ashour W, Twells LK, Valcour JE, Gamble JM. Diabetes and the occurrence of
432 infection in primary care: a matched cohort study. *BMC Infect Dis.* 2018;18(1):67.

- 433 24. Kumar NP, Sridhar R, Nair D, Banurekha VV, Nutman TB, Babu S. Type 2 diabetes
434 mellitus is associated with altered CD8(+) T and natural killer cell function in pulmonary
435 tuberculosis. *Immunology*. 2015;144(4):677-86.
- 436 25. Tan KS, Lee KO, Low KC, Gamage AM, Liu Y, Tan GY, et al. Glutathione deficiency in
437 type 2 diabetes impairs cytokine responses and control of intracellular bacteria. *J Clin Invest*.
438 2012;122(6):2289-300.
- 439 26. Lopez-Lopez N, Martinez AGR, Garcia-Hernandez MH, Hernandez-Pando R, Castañeda-
440 Delgado JE, Lugo-Villarino G, et al. Type-2 diabetes alters the basal phenotype of human
441 macrophages and diminishes their capacity to respond, internalise, and control *Mycobacterium*
442 tuberculosis. *Mem Inst Oswaldo Cruz*. 2018;113(4):e170326.
- 443 27. Syed-Ahmed M, Narayanan M. Immune Dysfunction and Risk of Infection in Chronic
444 Kidney Disease. *Adv Chronic Kidney Dis*. 2019;26(1):8-15.
- 445 28. Brinkkoetter P-T, Marinaki S, Gottmann U, Fleckenstein S, Stump C, Van Der Woude
446 FJ, et al. Altered CD46-mediated T cell co-stimulation in haemodialysis patients. *Clinical &*
447 *Experimental Immunology*. 2005;139(3):534-41.
- 448 29. Stachowski J, Pollok M, Burrichter H, Spithaler C, Baldamus CA. Signalling via the
449 TCR/CD3 antigen receptor complex in uremia is limited by the receptors number. *Nephron*.
450 1993;64(3):369-75.
- 451 30. Magliano DJ, Harding JL, Cohen K, Huxley RR, Davis WA, Shaw JE. Excess Risk of
452 Dying From Infectious Causes in Those With Type 1 and Type 2 Diabetes. *Diabetes Care*.
453 2015;38(7):1274-80.
- 454 31. Lin Y-Y, Shiau S, Fang C-T. Risk Factors for Invasive *Cryptococcus neoformans*
455 Diseases: A Case-Control Study. *PloS one*. 2015;10(3):e0119090.

- 456 32. Li Y, Fang W, Jiang W, Hagen F, Liu J, Zhang L, et al. Cryptococcosis in patients with
457 diabetes mellitus II in mainland China: 1993-2015. *Mycoses*. 2017;60(11):706-13.
- 458 33. Lin KH, Chen CM, Chen TL, Kuo SC, Kao CC, Jeng YC, et al. Diabetes mellitus is
459 associated with acquisition and increased mortality in HIV-uninfected patients with
460 cryptococcosis: A population-based study. *J Infect*. 2016;72(5):608-14.
- 461 34. Guo W, Zhou Q, Jia Y, Xu J. Increased Levels of Glycated Hemoglobin A1c and Iron
462 Deficiency Anemia: A Review. *Medical science monitor: international medical journal of*
463 *experimental and clinical research*. 2019;25:8371.
- 464 35. English E, Idris I, Smith G, Dhatariya K, Kilpatrick ES, John WG. The effect of anaemia
465 and abnormalities of erythrocyte indices on HbA 1c analysis: a systematic review. *Diabetologia*.
466 2015;58(7):1409-21.
- 467 36. Kalil AC, Syed A, Rupp ME, Chambers H, Vargas L, Maskin A, et al. Is bacteremic
468 sepsis associated with higher mortality in transplant recipients than in nontransplant patients? A
469 matched case-control propensity-adjusted study. *Clinical Infectious Diseases*. 2015;60(2):216-
470 22.
- 471 37. Bratton EW, El Hussein N, Chastain CA, Lee MS, Poole C, Stürmer T, et al.
472 Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ
473 transplant, and HIV-negative/non-transplant. *PloS one*. 2012;7(8):e43582.
- 474

475 **Table 1. Patient clinical characteristics for cases and controls.**

Patient characteristics (%, mean \pm SD)	N	Controls (n=125)	Pulmonary cryptococcosis cases (n=35)	P-values
Demographics				
Gender (male)	221	106 (84.8%)	27 (77.1%)	0.285
Age (years)	221	53.6 \pm 14.9	59.5 \pm 14.5	0.038
Race (white)	126	73 (63.5%)	22 (64.7%)	0.242
BMI (kg/m ²)	147	25.3 \pm 5.9	24.9 \pm 4.7	0.757
Risk factors				
Smoking (current)	111	30 (24.4%)	4 (11.4%)	0.223
Transplant	219	28 (22.4%)	9 (26.5%)	0.618
Diabetes mellitus	221	25 (20%)	9 (25.7%)	0.465
Uncontrolled DM	211	9 (7.6%)	6 (17.1%)	0.093
HIV	220	46 (36.8%)	6 (17.7%)	0.035
Malignancy	220	31 (24.8%)	12 (35.3%)	0.222
Cirrhosis	221	6 (4.8%)	1 (2.9%)	0.619
Steroids	217	27 (21.8%)	9 (27.3%)	0.504
Symptoms at presentation				
Headaches	219	33 (26.6%)	2 (5.9%)	0.010
Altered mental status	221	48 (38.4%)	4 (11.4%)	0.003
Respiratory	220	32 (25.8%)	28 (80%)	< 0.001
Labs				
Hemoglobin (g/dL)	215	12.3 \pm 2.6	11.9 \pm 2.9	0.513
Platelets (10 ⁹ /L)	214	207.9 \pm 135.2	207.7 \pm 84	0.992
Creatinine (mg/dl)	208	1.3 \pm 1.2	1.3 \pm 0.8	0.843
CD4 count (cells/ μ L)	86	206 \pm 224.9	200.9 \pm 319.1	0.952
HbA1c (%)	96	6.24 \pm 1.8	6.8 \pm 1.7	0.252
Outcome				
ICU stay	53	27 (36%)	7 (30.4%)	0.624
Overall Death	221	49 (39.2%)	15 (42.9%)	0.696
Death within 10 weeks	221	12 (9.6%)	5 (14.3%)	0.427
Death within 1 year	221	28 (22.4%)	8 (22.9%)	0.954

476 **Table 2. Patient clinical characteristics among survivors and non-survivors at 10-weeks.**

Patient characteristics (%, mean ± SD)	Cases survivors		Cases non-survivors at 10 weeks (n=18)	P- values**
	N	at 10 weeks (n=78)		
Type of infection	96			
Cryptococcal meningitis		36 (46.2%)	11 (61.1%)	0.818
Pulmonary disease		30 (38.5%)	5 (27.8%)	
Skin and others		7 (9%)	1 (5.6%)	
Asymptomatic antigenemia		5 (6.4%)	1 (5.6%)	
Symptoms at presentation				
Headaches	219	27 (34.6%)	5 (29.4%)	0.681
Altered mental status	221	14 (18%)	9 (50%)	0.004
Respiratory	220	32 (41%)	11 (61.1%)	0.122
Labs				
Hemoglobin (g/dL)	215	12.1 ± 2.6	10.4 ± 2.0	0.007
Platelets (10 ⁹ /L)	214	216 ± 92.1	151 ± 161	0.025
Creatinine (mg/dl)	208	1.3 ± 0.8	1.5 ± 1.1	0.309
CD4 count (cells/μL)	86	155 ± 250.8	202 ± 409	0.679
HbA1c (%)	96	6.2 ± 1.1	7.8 ± 2.0	0.005
CSF profile				
Opening pressure (cm H ₂ O)	54	28.4 ± 11.6	14.8 ± 1.9	0.055
CSF WBC (10 ⁶ /L)	131	447 ± 2376	55.4 ± 83.1	0.589
CSF glucose (mg/dL)	130	43.9 ± 21	73 ± 58.3	0.009
CSF protein (mg/dL)	132	121 ± 193	120 ± 159	0.988
Outcome				
ICU stay	53	9 (20%)	8 (100%)	<0.001
Overall Death	221	19 (24.4%)	18 (100%)	<0.001
Death within 10 weeks	221	0 (0%)	18 (100%)	NA
Death within 1 year	221	6 (7.7%)	18 (100%)	<0.001
VP shunt	83	3 (4.0%)	1 (11%)	0.351
Cognitive deficits	78	12 (16.4%)	2 (40%)	0.184
Hearing impairment	78	6 (8.1%)	0 (0%)	0.553

Speech difficulties	80	2 (2.7%)	1 (20%)	0.048
Muscle weakness	79	18 (24%)	1 (25%)	0.964
Stroke	34	5 (19.2%)	3 (37.5%)	0.287

477

478 **Table 3. Multivariable analysis of mortality predictors**

479

480 **10-weeks**

Variable	Odds ratio	Confidence Intervals	P-value
Uncontrolled DM*	3.6	1.1-12.3	0.03
Malignancy	3.4	1.3-9.1	0.01
Cryptococcosis case	4.0	1.5-10.5	0.005
Altered Mental Status	1.4	0.8-5.2	0.157

481

482 **1-year**

Variable	Odds ratio	Confidence Intervals	P-value
Malignancy	6.8	2.8-16.4	0.0001
Uncontrolled DM*	6.6	2.0-21.4	0.002
Positive Blood cultures**	2.6	0.8-8.5	0.106
HIV	1.9	0.8-4.5	0.159

483 D.M.: Diabetes Mellitus, *HbA1c>7%, **For *Cryptococcus spp.*


484

485

486 **Figure 1. Survival curves at 1-year of Cryptococcosis cases by controlled or uncontrolled Diabetes Mellitus.**487 **Figure 2. Survival curves at 1-year of Pulmonary Cryptococcosis cases by controlled or uncontrolled Diabetes Mellitus.**


488

Kaplan-Meier survival for all Cryptococcosis cases



— No DM, or controlled DM2 — Uncontrolled DM2

Kaplan-Meier survival estimates for Pulmonary Cryptococcosis cases



— No DM, or controlled DM2 — Uncontrolled DM2